Búsqueda de biomarcadores metabolómicos para la detección precoz de cáncer de pulmón en población de riesgo

Zusammenfassung

Introduction: Lung cancer (LC) causes the greatest mortality, primarily due to its late diagnosis, for which survival rates are low.Objectives: To identify clinically useful biomarkers (BM) for the early diagnosis of LC in a high-risk population using metabolic analysis and blood samples.Material and methods: Serum samples were selected from 30 patients with LC and 30 patients with COPD (especially those with emphysema). The metabolic study was carried out using hybrid quadrupole/time-of-flight analyzer high-resolution mass spectrometry by directly infusing the samples with an electrospray source. Results: The partial least-squares discriminant analysis (PLS-DA) showed a clear discrimination between the two groups (LC and COPD). 35 altered metabolites were identified in LC with respected to the COPD group, including amino acids, fatty acids, carnitines and lysophospholipids. The most commonly affected metabolic pathway was the metabolism of alanine, aspartate and glutamine and the ROC curve analysis showed that 11 of the 35 metabolites altered in LC showed an area under the curve (AUC) above 0.7 (threonine, creatinine, ornithine, glutamate, phenylalanine, arginine, tyrosine, pentanoylcarnitine, palmitoleic acid, LPC [18:2], LPC [18:1], LPC [20:4]) which could be used as BM in LC and considered relevant in disease progression. Conclusions:1. 11 metabolites have been identified that could be BM in lung cancer. 2. These metabolites are related to metabolic pathways previously associated with LC. 3. These BM obtained could be used for LC screening in the high-risk population.